Company Overview and News

0
Gran Colombia Gold Identifies a new Structure at Its El Silencio Mine; Announces Additional High-grade Results from the Ongoing Infill Drilling and Underground Channel Sampling Programs at Its Segovia Operations

21h globenewswire
TORONTO, June 18, 2018 (GLOBE NEWSWIRE) -- Gran Colombia Gold Corp. (TSX:GCM) announced today that its 2018 exploration program at its Segovia Operations has identified a new structure at the El Silencio mine, interpreted as a splay off the Manto Vein and termed the 1320 Vein. The Company also provided an update of the assay results from the surface and underground diamond infill drilling program at the Providencia, El Silencio and Sandra K mines.
TPWRF GCM GCM.WT.A TPRFF

0
Gran Colombia Gold Announces Voting Results of the Annual Shareholders Meeting

2018-06-14 globenewswire
TORONTO, June 14, 2018 (GLOBE NEWSWIRE) -- Gran Colombia Gold Corp.’s (TSX:GCM) Annual Meeting of Shareholders was held on Thursday, June 14, 2018. The detailed results of the votes for each matter to be acted upon are set out below:
TPWRF GCM GCM.WT.A TPRFF

1
Gran Colombia Gold to Acquire Approximately 15% Interest in Sandspring Resources Ltd.

2018-06-12 globenewswire
TORONTO, June 12, 2018 (GLOBE NEWSWIRE) -- Gran Colombia Gold Corp. (TSX:GCM) announced today that it has entered into a letter of intent (“LOI”) with Sandspring Resources Ltd. (TSX-V:SSP) (OTCQX:SSPXF) (“Sandspring”) pursuant to which it intends to acquire an approximately 15% equity interest in Sandspring (the “Transaction”). This investment in Sandspring will be made by way of the acquisition by Sandspring of the Company’s 30% carried participating interest in the Guia Antigua Mine (the “Project”) in Segovia and a concurrent CA$4.
WPM SSP SLW TPWRF GCM GCM.WT.A SSPXF SLW TPRFF

1
Sandspring Resources to Acquire Interest in Silver – Gold Project in the Segovia-Remedios Mining District of Antioquia, Colombia and Announces Private Placement

2018-06-12 globenewswire
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
WPM SSP SLW TPWRF GCM SSPXF GCM.WT.A SLW TPRFF

0
Gran Colombia Gold’s Trailing 12-Months’ Gold Production Tops 192,000 Ounces at the End of May 2018

2018-06-11 globenewswire
TORONTO, June 11, 2018 (GLOBE NEWSWIRE) -- Gran Colombia Gold Corp. (TSX:GCM) announced today that it produced a total of 18,675 ounces of gold in May bringing the total for the first five months of 2018 to 87,465 ounces, up 27% compared to the first five months of 2017. This brings the Company’s trailing 12-months’ total gold production to 192,461 ounces, up 11% from 2017’s annual production of 173,821 ounces and near the top end of the Company’s production guidance for 2018 of between 182,000 and 193,000 ounces.
TPWRF GCM GCM.WT.A TPRFF

38
10 Best Risk/Reward Leveraged Gold Stocks

2018-06-01 seekingalpha
Below is a list of 10 quality gold producers. I have selected them as the best risk/reward leveraged gold stocks. All of these should outperform the price of gold if it rises. In fact, I expect all of these stocks to double in value if gold reaches $1,600. These are the stocks that you want to own if you are looking for high returns if gold prices start trending. Also, if you are looking for a way to hedge against a market crash, then these stocks offer a potential hedge.
NGDAF ARNGF NGD TGD MUX.RTWI HUMRF DGC EDVVF PMNXF GCM.WT.A PRU MUX AR HTXFF HUM EDV RPM NGD ALO MUX TPWRF WDO EDVMF RPMGD DRGDF RPMGF PRU TPRFF GCM TMM EVR WDOFF

6
Gold: Are The Lows In?

2018-05-27 seekingalpha
In what has been a tricky start to the year for most asset classes, Gold (GLD) has acted as a haven to hide from the turbulence. While the metal hasn't outperformed the market indices with its 1% year to date return, it has provided a smoother sleep schedule with its lower relative volatility. The recent pullback in gold has sent it back down to its 20-month moving average and to just below its previous resistance level ($1,300/oz).
TPWRF GORO GCM GCM.WT.A TPRFF

0
Gran Colombia Gold Reports First Quarter 2018 Results; Files National Instrument 43-101 Technical Report for Its Segovia Operations

2018-05-10 globenewswire
TORONTO, May 10, 2018 (GLOBE NEWSWIRE) -- Gran Colombia Gold Corp. (TSX:GCM) announced today the release of its unaudited interim condensed consolidated financial statements and accompanying management’s discussion and analysis (MD&A) for the three months ended March 31, 2018. All financial figures contained herein are expressed in U.S. dollars (“USD”) unless otherwise noted.
TPWRF GCM GCM.WT.A TPRFF

0
Gran Colombia Gold Announces Details for Its First Quarter 2018 Webcast

2018-05-03 globenewswire
TORONTO, May 03, 2018 (GLOBE NEWSWIRE) -- Gran Colombia Gold Corp. (TSX:GCM) announced today that it will release its financial results for the first quarter of 2018 after market close on Thursday, May 10, 2018 and will host a conference call and webcast on Friday May 11, 2018 at 9:30 a.m. Eastern Time to discuss the results.
TPWRF GCM GCM.WT.A TPRFF

0
Gran Colombia Gold Announces Closing of US$98 Million Debt Financing and Early Settlement of US$7.3 Million of 2018 Debentures

2018-04-30 globenewswire
TORONTO, April 30, 2018 (GLOBE NEWSWIRE) -- Gran Colombia Gold Corp. (the “Company” or “Gran Colombia”) (TSX:GCM) announced today that it has closed its previously announced proposed debt financing (the “Offering) of 97,992 units (the “Units” and each, a “Unit”) for aggregate gross proceeds of approximately US$98 million. The Offering was led by GMP Securities L.P. as sole lead agent and sole book-runner.
TPWRF GCM GCM.WT.A TPRFF

0
Gran Colombia Gold Receives Requisite Securityholder Approval and Consents and Expects to Close Previously Announced Debt Financing on April 30, 2018

2018-04-20 globenewswire
TORONTO, April 20, 2018 (GLOBE NEWSWIRE) -- Gran Colombia Gold Corp. (the “Company” or “Gran Colombia”) (TSX:GCM) announced today the positive results of the Company’s special meeting of shareholders (the “Special Meeting”) and consent solicitations related to its previously announced proposed debt financing (the “Offering”). With the requisite securityholder approval and consents now received, the Company expects to complete the closing of the Offering on April 30, 2018.
TPWRF GCM GCM.WT.A TPRFF

0
Gran Colombia Gold Continues to Report Growth in Its First Quarter 2018 Production Update

2018-04-09 globenewswire
TORONTO, April 09, 2018 (GLOBE NEWSWIRE) -- Gran Colombia Gold Corp. (TSX:GCM) announced today that it produced a total 18,633 ounces of gold in March bringing the total for the first quarter of 2018 to 52,672 ounces, up 35% compared to the first quarter of 2017. This brings the Company’s trailing 12-months’ total gold production to 187,485 ounces, up 8% from 2017’s annual production of 173,821 ounces and within the Company’s production guidance for 2018 of between 182,000 and 193,000 ounces.
TPWRF GCM GCM.WT.A TPRFF

0
Gran Colombia Gold Corp. 2017 Q4 - Results - Earnings Call Slides

2018-03-29 seekingalpha
The following slide deck was published by Gran Colombia Gold Corp. in conjunction with their 2017 Q4 earnings call.
TPWRF GCM GCM.WT.A TPRFF

0
Gran Colombia Gold Reports Fourth Quarter and Full Year 2017 Results; Turnaround Doubles Adjusted EBITDA to $75.5 Million in Two Years; Reports First Mineral Reserve for its Segovia Operations

2018-03-28 globenewswire
TORONTO, March 27, 2018 (GLOBE NEWSWIRE) -- Gran Colombia Gold Corp. (TSX:GCM) announced today the release of its audited consolidated financial statements and accompanying management’s discussion and analysis (MD&A) for the year ended December 31, 2017. All financial figures contained herein are expressed in U.S. dollars (“USD”) unless otherwise noted.
TPWRF GCM GCM.WT.A TPRFF

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to TSX:GCM / Gran Colombia Gold Corp. on message board site Silicon Investor.

AGCM - AmericanGreetings.com Gemcom Software International (GCM/TSE)